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Succinylcholine has fast onset and short duration of action and hence is considered as drug of choice for rapid sequence induction of anaesthesia.[@ref1] Intubation becomes easier owing to intense neuromuscular blockade produced by succinylcholine.[@ref2] However, it produces muscle stiffness and postoperative myalgia as side effects.[@ref3][@ref4] The incidence of succinylcholine-induced myalgia ranges from 41% to 92%.[@ref5] Succinylcholine-induced myalgia is prominent in the muscles of the shoulder, neck, back, and abdomen. It is predominantly seen in surgeries that permit early ambulation. The exact underlying mechanism of succinylcholine-induced myalgia is not known, but several mechanisms including increased myoplasmic calcium concentrations, degradation of membrane phospholipids, release of free fatty acids, and free radicals are thought to be causative factors.[@ref6] Use of different pretreatment modalities including benzodiazepines, nondepolarizing neuromuscular blockers, local anesthetics, chlorpromazine, phenytoin, ketorolac, Vitamin E derivatives, pretreatment with rocuronium and remifentanil have been tried to reduce the severity of succinylcholine-induced myalgia.[@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14]

The surgical procedure serves as noxious stimulus, results in initial sensitization and establishment of altered processing of afferent input to central nervous system (CNS), following an incisional and inflammatory injury which amplifies postoperative pain. Preemptive analgesia is a treatment that is initiated before the surgical procedure to "preempt" or prevent neurophysiological and biochemical consequences of a noxious input to the CNS provoked by the procedure. It means that the concept of preemptive analgesia is not to prevent pain but to prevent CNS alterations leading to pain amplification following first pain experience and development of chronic pain syndromes.[@ref15] Preemptive analgesic efficacy of drugs such as opioids, local anesthetics, and nonsteroidal anti-inflammatory drugs have been demonstrated in earlier studies.[@ref16][@ref17][@ref18]

The use of gabapentin and pregabalin, as protective premedication before the start of different surgeries, has been demonstrated in separate studies.[@ref19] To the best of our knowledge, no comprehensive data exist with regard to comparison of preemptive analgesic efficacy and safety of pregabalin and gabapentin for succinylcholine-induced myalgia. The present randomized controlled trial was therefore designed to investigate the preemptive analgesic efficacy and safety of pregabalin and gabapentin for succinylcholine-induced myalgia.

Pregabalin and gabapentin are newer antiepileptic drugs. This class of drugs works through three major mechanisms, i.e., potentiation of gamma aminobutyric acid transmission, reduction of glutamate-mediated excitatory transmission, and blockade of voltage-activated ion channels. The latter mechanism of action, in particular, is responsible for the success of these agents as preemptive analgesic.[@ref15]

Gabapentin binds to the α2-δ subunit of voltage-dependent calcium channels and reduces calcium influx into nerve terminals, which inhibits release of endogenous excitatory amino acids aspartate and glutamate thereby reduces postsynaptic excitability.[@ref20][@ref21] While pregabalin is an analog of gabapentin and has a similar mechanism of action as gabapentin. It reduces pain by decreasing calcium influx into the intrafusal muscle fibers.[@ref22]

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

The Institute\'s Ethics Committee approved this study protocol, and written informed consent was obtained from each participant (Ref. SKNMC/Ethics/APP/2018/380). The study duration was 12 months. The sample size calculation was done using open-Epi statistical software (power - 80%, confidence interval - 95%, odds ratio - 6); the study had 4 groups with 30 patients in each group for a power of 80% (β = 80% and α = 0.05). Patients, between 18 and 70 years of age of either gender, American Society of Anesthesiologists I and II, undergoing surgeries under general anesthesia requiring endotracheal intubation, from departments of surgery and ear, nose, and throat were recruited. Patients with known or suspected coagulopathy, hypersensitivity to any of the study drugs, mental retardation/preexisting neurological disease, impaired renal functions, history of analgesic consumption, history of peptic ulcer disease, or treatment with antacids were excluded.

All patients were assessed preoperatively the day before surgery. Study protocol was explained to participants. Participants were randomly assigned to one of the four groups using a computer-generated table of random numbers, to receive medications.

Group A (Pregabalin group): Pregabalin 150 mg 30 min before surgeryGroup B (Gabapentin group): Gabapentin 600 mg 30 min before surgeryGroup C (Control group): Diclofenac sodium 100 mg 30 min before surgeryGroup D (Placebo group): Saccharine tablet 10 mg 30 min before surgery.

In the operating room, standard monitoring was used. An 18G intravenous cannula was inserted in the dorsum of the nondominant hand. Premedication was with injection glycopyrrolate 0.02 mg/kg + injection midazolam 0.02 mg/kg i.v. preoxygenation was done with 100% oxygen for 3 min before induction. Anesthesia was induced with propofol 1.5--2 mg/kg and fentanyl 3 μg/kg, and intubation, with appropriate-sized and cuffed endotracheal tube, was facilitated by injection succinylcholine 1.5 mg/kg. Anesthesia was maintained with 50% nitrous oxide in oxygen and sevoflurane. Vecuronium bromide 100 μg/kg was given after endotracheal intubation. Fentanyl 1 μg/kg/h was infused during surgery, and vecuronium bromide 20 μg/kg was given intermittently to maintain muscle relaxation. At the completion of surgery, residual neuromuscular blockade was reversed with glycopyrrolate 10 μg/kg and neostigmine 40 μg/kg intravenously, and patients were extubated when adequate spontaneous ventilation was established. Patients were transferred to the postanesthesia care unit from where they were transferred to their respective wards. Baseline and postoperative vital parameters such as pulse rate, respiratory rate, mean arterial pressure, and saturation of peripheral oxygen (SpO2) were recorded.

Myalgia was defined as "muscle pain not related to surgical intervention."[@ref23] The incidence and severity of myalgia were recorded by a blinded observer after surgical intervention for the first 24 h.

The grading of myalgia was done as follows:[@ref6]

0 - Absence of muscle pain1 - Stiffness limited to one area only2 - Muscle pain or stiffness noticed spontaneously by the patient, which may require analgesic therapy3 - Generalized, severe, or incapacitating discomfort.

Postoperative level of analgesia was noted on visual analog scale (VAS) and facial rating scale (FRS) at 6, 12, 18, and 24 h. Rescue analgesic (Diclofenac 100 mg) was given if patient complained of pain or pain score was more than 4.[@ref24] Postoperative analgesic requirement for 24 h was recorded. Duration of postoperative anesthesia care unit stay was recorded using modified Aldrete\'s scoring system; patients with score \>9 were shifted to the ward.[@ref24]

Study design {#sec2-1}
------------

See [Figure 1](#F1){ref-type="fig"}.

![Study flow chart](NMJ-60-27-g001){#F1}

Statistical analysis {#sec2-2}
--------------------

Demographic profile and vital parameters were analyzed using analysis of variance. VAS and FRS were analyzed using Student\'s *t*-test. Analgesic consumption was compared using Mann--Whitney U-test.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

In this randomized clinical study, preemptive analgesic efficacy of pregabalin (150 mg), gabapentin (600 mg), and diclofenac (100 mg) single dose taken orally in postoperative pain and succinylcholine-induced myalgia was compared. There were 83 males and 37 females enrolled in the study. Demographic profile and vital parameters were comparable among groups presented in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

###### 

Demographic profile of patients

  Characteristics (*n*=120)       Group A (pregabalin)   Group B (gabapentin)   Group C (control)   Group D (placebo)
  ------------------------------- ---------------------- ---------------------- ------------------- -------------------
  Age (years), mean±SD            46.6±9.67              44.36±8.84             46.96±8.75          46.13±9.83
  Sex (male:female)               21:9                   22:8                   17:13               23:7
  Weight, mean±SD                 71.6±9.95              74.5±11.59             71.23±10.94         68.76±8.15
  Surgery performed                                                                                 
   Tonsillectomy                  3                      5                      4                   6
   Laparoscopic cholecystectomy   6                      7                      8                   8
   Tympanoplasty                  9                      8                      8                   8
   Hemithyroidectomy              1                      3                      2                   0
   Near-total thyroidectomy       2                      0                      1                   2
   Mastoid exploration            9                      7                      7                   5
  Duration of surgery (min)       120±15.53              122.66±15.29           127±15.78           126±14.99

Baseline vital parameters were comparable between the groups. SD -- Standard deviation

###### 

Effect on postoperative vital parameters

  Drugs group (mean±SD)   Baseline    At 0 h postoperatively
  ----------------------- ----------- ------------------------
  Group A                             
   Pulse rate             79.1±8.2    79.1±8.2
   Respiratory rate       13.3±1.2    13.3±1.2
   SpO2                   99.9±0.25   99.8±0.4
   MAP                    78.4±6.2    78.5±6.0
  Group B                             
   Pulse rate             81.8±8.9    81.8±8.9
   Respiratory rate       13.6±1.6    13.6±1.6
   SpO2                   99.9±0.3    99.9±0.2
   MAP                    80.1±5.1    80.4±5.5
  Group C                             
   Pulse rate             81.9±8.6    81.9±8.6
   Respiratory rate       13.6±1.7    13.6±1.7
   SpO2                   99.9±0.3    99.9±0.3
   MAP                    80.7±5.5    80.7±5.5
  Group D                             
   Pulse rate             84.0±7.5    84.6±7.5
   Respiratory rate       13.5±1.8    13.4±1.8
   SpO~2~                 99.8±0.4    99.9±0.2
   MAP                    80.9±6.2    81.9±5.1

MAP -- Mean arterial pressure, SD -- Standard deviation, SpO2 -- Saturation of peripheral oxygen

Effect of test drugs on pain scores and myalgia scale are presented in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, respectively. Pain scores on both scales were found significantly lower at 6, 12, and 24 h in the pregabalin group when compared to control as well as placebo groups, whereas in the gabapentin group, it was found significantly lower only at 24 h when compared to control. However, pregabalin and gabapentin were both found equianalgesic in this regard since no significant difference was found when compared to each other.

###### 

Effect on postoperative visual analog scale, facial rating scale, and adverse drug reactions

  Drugs group            Time (h), mean±SD                                                                    
  ---------------------- ------------------- ---------------- ---------------- ------------- ---------------- -------------------------------------
  Group A (pregabalin)                                                                                        
   VAS                   1.5±0.7             2.9±1.1\*^,\#^   3.0±1.3\*^,\#^   2.7±1.1^\#^   1.4±1.5\*^,\#^   Nausea - 0Vomiting - 6Sedation - 2
   FRS                   2.3±1.5             1.5±0.7\*^,\#^   3.2±1.1\*^,\#^   3.9±1.4       1.9±1.1\*^,\#^   
  Group B (gabapentin)                                                                                        
   VAS                   1.4±0.8             3.4±1.2          3.3±1.2^\#^      2.8±0.9^\#^   1.7±1.9\*^,\#^   Nausea - 1Vomiting - 11Sedation - 8
   FRS                   2.7±1.9             2.4±0.8^\#^      3.5±1.2          3.4±1.2^\#^   2.1±0.9\*^,\#^   
  Group C (control)                                                                                           
   VAS                   1.4±1.0             3.9±1.5          3.9±1.8          2.9±0.7^\#^   2.6±1.7^\#^      Nausea - 2Vomiting - 13Sedation - 2
   FRS                   2.6±1.7             2.4±1^\#^        3.9±1.5          3.7±1.9       2.9±0.7^\#^      
  Group D (placebo)                                                                                           
   VAS                   1.4±1.0             4±1.5            4±1.9            3.8±1.3       3.8±1.6          Nausea - 4Vomiting - 18Sedation - 0
   FRS                   2.8±1.6             3.4±1.0          4±1.5            4±1.9         3.9±1.3          

*n*=120, ^\#^*P*\<0.05 compared to placebo,\**P*\<0.05 compared to control. VAS -- Visual analog scale, FRS -- Facial rating scale, ADRs -- Adverse drug reactions, SD -- Standard deviation

###### 

Grades of succinylcholine-induced myalgia

                             Group A (pregabalin)   Group B (gabapentin)   Group C (control)   Group D (placebo)
  -------------------------- ---------------------- ---------------------- ------------------- -------------------
  Myalgia                                                                                      
   Yes - male (female)       6 (7)                  7 (8)                  8 (15)              9 (16)
   No                        17                     15                     7                   5
  Frequency of myalgia (%)   43.34                  50                     76.67               83.34%
  Severity of myalgia                                                                          
   Mild                      12                     9                      16                  16
   Moderate                  1                      6                      7                   8
   Severe                    0                      0                      0                   1

Incidence and severity of myalgia were minimal in the pregabalin group with significantly less requirement of rescue analgesic \[[Table 5](#T5){ref-type="table"}\]. Nausea, vomiting, and sedation were observed as side effects among the groups which were of mild variety. Patients in the pregabalin group were found to be more comfortable throughout in this regard as adverse drug reactions, i.e., nausea, vomiting, and sedation were less in pregabalin group compared to gabapentin, control, and placebo groups.

###### 

Postoperative rescue analgesic requirement

  Drug group   Analgesic needed in 24 h (g)              Per patient requirement median (IQR)   
  ------------ ----------------------------------------- -------------------------------------- ------
  Group A      800                                       0 (0-100)\*^,\#^                       
  Group B      1900                                      50 (0-100)^\#^                         
  Group C      2400                                      50 (0-100)^\#^                         
  Group D      3100                                      100 (100-100)                          
               Time of rescue analgesic administration                                          
  0-6 h        6-12 h                                    12-24 h                                
  Group A      0                                         400                                    400
  Group B      0                                         700                                    1200
  Group C      0                                         1000                                   1400
  Group D      0                                         1400                                   1700

\**P*\<0.05 compared to control (Group C), ^\#^*P*\<0.05 compared to placebo (Group D), by Mann--Whitney U-test for per patient analgesic requirement. IQR -- Interquartile range

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Succinylcholine is a depolarizing neuromuscular-blocking agent. It is considered as the best drug for rapid sequence induction and also for providing suitable muscle relaxation for surgical procedures of short duration. However, the use of succinylcholine is frequently accompanied by postoperative myalgia.[@ref4][@ref25] The reported incidence of succinylcholine-induced myalgia varies between 41% and 92%.[@ref5] Succinylcholine-induced myalgia is usually experienced from the first day after surgery and usually lasts for about 3--4 days. While this myalgia is self-limiting, iatrogenic postoperative myalgia is considered unacceptable in modern anesthetic practice.[@ref26] Postoperative myalgia is influenced by gender, females being affected more often.[@ref27] It is also observed more commonly in patients who take to early ambulation.[@ref7] In our study, myalgia was observed in 46 female and 30 male patients; this is in agreement with the study observations that mention myalgia is influenced by gender.

Postoperative myalgia is likely a consequence of muscle damage produced by the shearing forces associated with the fasciculations at the onset of phase one block.[@ref28] At molecular level, occurrence of postoperative myalgia is due to increased myoplasmic calcium concentrations, membrane phospholipids\' degradation, released free fatty acids and free radicals which cause damage to delicate muscle spindles.[@ref6][@ref29] Pain signals from damaged tissue launch a series of changes in the somatosensory system. One of them is an increase in the responsiveness of both peripheral and central neurons. These changes will increase the response to subsequent stimuli thereby amplifying pain.[@ref30]

Preemptive analgesia is a treatment that is intended to reduce the physiological consequences of nociceptive transmission provoked by the procedure. It is administered before the surgical procedure. Due to this "protective" effect on the pain pathways, preemptive analgesia has the potential to be more effective than a similar analgesic treatment initiated after surgery. Consequently, it helps to reduce immediate postoperative pain and to prevent development of chronic pain.[@ref31]

In the present study, we have studied and compared preemptive analgesic efficacy and safety of diclofenac sodium, and two antiepileptic drugs such as gabapentin and pregabalin. In our previous study, we found gabapentin to have better preemptive analgesic efficacy in postoperative pain management compared to diclofenac sodium;[@ref15] however, this efficacy in postoperative succinylcholine-induced myalgia was not studied. NSAIDs-mediated relief of myalgia is suggestive of an inflammatory genesis and involvement of prostaglandins,[@ref9][@ref29] indicative of their peripheral action mainly. It is also postulated that calcium influx will eventually lead to muscle damage and pain through contraction of the intrafusal muscle fibers.[@ref32][@ref33] Gabapentin is known to bind to the α2-δsubunit of voltage-dependent calcium channels.[@ref20] It reduces calcium influx into nerve terminals and inhibits release of endogenous excitatory amino acids aspartate and glutamate thereby reduces postsynaptic excitability [@ref21] suggestive of more specific action on muscle fires through voltage-dependent calcium channels. Hence, gabapentin is thought to be more useful in preventing postoperative pain and myalgia compared to NSAIDs. Our study results revealed the same as: pain scores and frequency of myalgia were found to be significantly lower in gabapentin group when compared to diclofenac group.

Pregabalin being an analog of gabapentin has a similar mechanism of action and reduces pain by decreasing calcium influx into the intrafusal muscle fibers. However, pregabalin has a better bioavailability (90%), is rapidly absorbed, and has better pharmacokinetic profile than gabapentin. It requires a lower dose and is associated with fewer dose-related adverse effects, while still maintaining an equianalgesic effect.[@ref22] Some earlier studies have demonstrated the equianalgesic efficacy of pregabalin (150 mg), gabapentin (600 mg), and diclofenac sodium (100 mg) in reducing the incidence and severity of succinylcholine-induced myalgia.[@ref22][@ref34] In our study, pregabalin (150 mg) has better efficacy than diclofenac (100 mg) as VAS scores show significant difference at 6, 12, and 24 h. Better efficacy of pregabalin is due to its multifaceted action for pain control including that of neuropathic origin, while diclofenac is involved in suppression of pain from only inflammatory origin. Gabapentin shows significant difference in VAS at 24 h when compared to diclofenac. This also indicates faster onset and sustained action of pregabalin compared to gabapentin, thereby reducing the consumption of postoperative rescue analgesic. The incidence of adverse drug effects is also less in the pregabalin group as compared to gabapentin and diclofenac.

Although pregabalin and gabapentin have equal analgesic efficacy, pregabalin (150 mg) has faster onset and sustained action requiring less postoperative rescue analgesic and better safety when compared to gabapentin (600 mg). Hence, on the basis of safety and efficacy parameters, single preemptive oral dose of pregabalin (150 mg) can be recommended as preemptive analgesic in postoperative pain management and in reducing the incidence and severity of succinylcholine-induced myalgia.

C[ONCLUSIONS]{.smallcaps} {#sec1-5}
=========================

Our clinical study has demonstrated pregabalin (150 mg) as a better choice when compared to gabapentin (600 mg) and diclofenac (100 mg) in reducing the incidence and severity of succinylcholine-induced myalgia and postoperative pain. Preemptive pregabalin has a faster onset, sustained actions, reduced postoperative analgesic requirement, and better safety profile than gabapentin and diclofenac. It may therefore be preferred over gabapentin and diclofenac.
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